

Market Applicability/Effective Date														
Market	FL & FHK	FL MMA	FL LTC	GA	KS	KY	LA	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	NA	NA	X	NA	X	X	X	X	X	X	NA	NA	X

\*FHK- Florida Healthy Kids

## Vidaza (azacitidine)

CG-DRUG-48

Override	Approval Duration
Prior Authorization	1 year

Medications	Quantity Limit
Vidaza	N/A
Azacitidine	N/A

### APPROVAL CRITERIA

Requests for Vidaza (azacitidine) **may be approved** for the following conditions:

- I. Myelodysplastic syndrome (MDS);

**OR**

- II. Acute myelogenous leukemia (AML) if the following criteria are met:
  - a. Used as a single agent for individuals 60 years of age and older or individuals who cannot tolerate more aggressive regimens; **OR**
  - b. Used in combination with sorafenib for relapsed or refractory AML with FLT3-ITD mutations; **OR**
  - c. AML arising from MDS.

Vidaza (azacitidine) **may not be approved** if the above criteria are not met.

State Specific Mandates		
N/A	N/A	N/A

### Key References:

Azacitidine Monograph. Lexicomp® Online, American Hospital Formulary Service® (AHFS®) Online, Hudson, Ohio, Lexi-Comp., Inc. Last revised May 11, 2011. Accessed on March 3, 2016.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability/Effective Date														
Market	FL & FHK	FL MMA	FL LTC	GA	KS	KY	LA	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	NA	NA	X	NA	X	X	X	X	X	X	NA	NA	X

\*FHK- Florida Healthy Kids

Azacitidine (systemic). In: DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated January 12, 2016. Available at: <http://www.micromedexsolutions.com>. Accessed on March 3, 2016.

Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. *Blood*. 2015; 126(3):291-299.

Fenaux P, Mufti GJ, Hellström-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. *J Clin Oncol*. 2010; 28(4):562-569.

Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al; International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. *Lancet Oncol*. 2009; 10(3):223-232.

Greenberg P, Cox C, LeBeau M, et al. Erratum. International scoring system for evaluating prognosis in myelodysplastic syndromes. *Blood* 1998; 91:1100.

Greenberg P, Cox C, LeBeau M, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. *Blood* 1997; 89:2079-2088.

Greenberg P, Heinz T, Schanz J, et al. Revised International Prognostic Scoring System for Myelodysplastic Syndromes. *Blood*. 2012; 20: 2454-2465.

Kaminskas E, Farrell A, Abraham S, et al; FDA. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. *Clin Cancer Res*. 2005; 11(10):3604-3608.

Kornblith AB, Herndon JE 2nd, Silverman LR, et al. Impact of azacitidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. *J Clin Oncol*. 2002; 20(10):2441-2452.

National Cancer Institute. Available at: <http://www.cancer.gov/>. Accessed on March 3, 2016.

- Acute Myeloid Leukemia Treatment (PDQ). Last modified January 15, 2016.
- Myelodysplastic Syndromes Treatment (PDQ). Last modified April 2, 2015.

National Comprehensive Cancer Network®. NCCN Drugs & Biologic Compendium™ (electronic version). For additional information visit the NCCN website: <http://www.nccn.org>. Accessed on March 3, 2016.

NCCN Clinical Practice Guidelines in Oncology™. © 2016 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: <http://www.nccn.org/index.asp>. Accessed on March 3, 2016.

- Acute Myeloid Leukemia (V.1.2015). Revised December 3, 2014
- Myelodysplastic Syndromes (V.1.2016). Revised May 28, 2015.

Malcovati L, Della Porta MG, Strupp C, et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). *Haematologica*. 2011; 96(10):1433-1440.

Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. *J Clin Oncol*. 2002; 20(10):2429-2440.  
WEB-PEC-0477-16-F

PAGE 2 of 3 07/28/2016

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability/Effective Date														
Market	FL & FHK	FL MMA	FL LTC	GA	KS	KY	LA	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	NA	NA	X	NA	X	X	X	X	X	X	NA	NA	X

\*FHK- Florida Healthy Kids

Silverman LR, McKenzie DR, Peterson BL, et al; Cancer and Leukemia Group B. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. *J Clin Oncol.* 2006; 24(24):3895-3903.

Sudan N, Rossetti JM, Shadduck RK, et al. Treatment of acute myelogenous leukemia with outpatient azacitidine. *Cancer.* 2006; 107(8):1839-1843.

Vidaza® [Product Information]. Summit, NJ. Celgene Corporation. December 2015. Available at: <http://www.vidaza.com/pi.pdf>. Accessed on March 3, 2016.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.